l-selectin

Bimosiamose disodium has anti-inflammatory effects[1]. Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-selectin inhibitor with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively.

Bimosiamose has anti-inflammatory effects[1]. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, L-selectin, and P-selectin respectively.

Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) 是源自大鼠的抗小鼠 L-Selectin/CD62L 的 IgG2a, κ 抗体抑制剂。

Sialyl-Lewis X (sLeX), a sialylated fucosylated tetrasaccharide and endogenous antigen, serves as a high-affinity ligand for selectins (E-, P-, and L-selectin)[1]. It interacts with ELAM-1 and CD62, consequently inhibiting CD62-mediated neutrophil recruitment to inflammation sites[2].

Aselizumab (HuDreg-55) 是一种人源化 IgG4 单克隆抗体，靶向循环中性粒细胞表面的细胞黏附分子 L-selectin (CD62L)。L-selectin 在介导细胞通过趋化作用迁移至损伤部位过程中发挥关键作用。研究发现，Aselizumab 的应用与感染及白细胞减少症的发生率增加相关，尤其在创伤后。

2',6'-Dihydroxy 4'-methoxydihydrochalcone 是口服活性的二氢查尔酮化合物，具有抗疟和抗炎特性，可在体外降低 IL-1β、TNF 及亚硝酸盐生成，并调控巨噬细胞炎性蛋白分泌及抑制中性粒细胞 L-selectin 裂解。急性毒性研究表明其无显著毒副作用，适用于炎症与感染性疾病的药理研究。